News & Media
Newsroom
SK Life Science Labs to Present Four Preclinical Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
3.20.2024
Full Release
SK Life Science Labs Experts Unveil Latest Scientific Findings at Keystone Symposia on Epigenetic Mechanisms and Cancer Treatment, and the 2nd Annual Molecular Glue Drug Development Summit
2.8.2024
Full Release
SK Life Science Labs, a Subsidiary of SK Biopharmaceuticals, Presents Discovery of Oral SMARCA2 Degraders Data at 6th Annual Targeted Protein Degradation Summit
10.31.2023
Full Release
SK Biopharmaceuticals’ Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10.12.2023
Full Release
Welcome to the news and information center for SK Life Science Labs
Please see scientific meeting presentations listed below:
- American Association for Cancer Research (AACR) Annual Meeting (2024)
- Keystone Symposia, Epigenetic Mechanisms and Cancer Treatment (2024)
- 2nd Molecular Glue Drug Development Summit (2024)
- SK Life Science Labs Company Overview (2024)
- Targeted Protein Degradation Summit (2023)
- AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2023)
- 20th Annual Discovery on Target Conference IKZF2 and MOPED™ presentations (2023)
- 3rd Annual Targeted Protein Degradation Europe (2023)
- Molecular Glue Drug Development Summit (2023)
To learn more about SK Life Science Labs, please check back soon to download our corporate fact sheet.
For more information about our technology, please check back soon to download our infographic.
SK Life Science Labs at a Glance
Headquarters: King of Prussia, PA
Company begins in 2020: Formerly known as Proteovant Therapeutics, in 2023 SK Life Science Labs becomes part of SK Biopharmaceuticals.
Parent Company: SK Life Science Labs is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of SK Group.
Number of Employees: 40+
Therapeutic Areas: Oncology, immuno-oncology and immunology including breast cancer, prostate cancer, and other solid and hematological cancers as well as unmet medical needs in immunological disorders.
Pipeline: 5+ programs